Stockscreener 앱 받기
0.00
100.00%
-0.88
시간 외 거래:
.88
0.88
+
전일 마감가:
$0.88
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$54.26M
수익:
-
순이익/손실:
$-112.67M
주가수익비율:
0.00
EPS:
-1.95
순현금흐름:
$-79.26M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$1.60
크로노스 Stock (KRON) Company Profile
명칭
Kronos Bio Inc
전화
(650) 781-5200
주소
1300 S. EL CAMINO REAL, SAN MATEO
KRON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.00 | 54.26M | 0 | -112.67M | -79.26M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
크로노스 Stock (KRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-11-14 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2022-09-14 | 개시 | Berenberg | Buy |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-06-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Goldman | Buy |
| 2020-11-03 | 개시 | Jefferies | Buy |
| 2020-11-03 | 개시 | Piper Sandler | Overweight |
모두보기
크로노스 주식(KRON)의 최신 뉴스
Market Momentum Report: Kronos Bio Inc (KRON)’s Negative Close at 0.88 - DWinneX
Two Sigma Investments LP Cuts Stock Holdings in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Kronos Bio to Exit Cambridge Lab, Returning Prime Space to Market Amid Biotech Downturn, Reports BBJ - Boston Real Estate Times
Squarepoint Ops LLC Makes New $93,000 Investment in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Kronos Bio sends Cambridge lab space back to market - The Business Journals
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - mx.advfn.com
kronos bio ends lease early, expects cost savings - Investing.com
Kronos Bio Terminates Cambridge Lease Agreement - TipRanks
Kronos Bio IncTerminates Office Lease At 301 Binney StreetSEC Filing - MarketScreener
Millennium Management LLC Has $1.63 Million Holdings in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Shareholders Filed a Lawsuit Against Kronos Bio for Merger Disclosure Failures - TradingView
Kronos Bio ($KRON) Misleading Merger Proxy and Insider Enrichment Case - TradingView
Kronos Bio Shareholder Says Sale Unfairly Benefits Execs - Law360
Kronos Bio, Board Sued by Shareholder Over Concentra Buyout Deal - Bloomberg Law News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders - GlobeNewswire Inc.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (NasdaqKRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (NasdaqXAGE), Southern States Bancshare - TradingView
Kronos Bio discovers p300 inhibitors - BioWorld MedTech
Weekly CEO Buys Highlight - GuruFocus
Deal Watch: Lilly Looks To Creyon For Oligonucleotides - insights.citeline.com
Concentra Biosciences Agrees to Acquire Kronos Bio - Contract Pharma
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc.KRON - Business Wire
KRON Shares Experience Decline in Value - knoxdaily.com
why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com
Kronos shares slump on Concentra takeover news - The Pharma Letter
Kronos Bio (KRON) to Merge with Concentra Biosciences in $0.57 P - GuruFocus
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc.KRON - PR Newswire
Struggling Peninsula biotech with Gilead lineage is latest purchase for activist investorSan Francisco Business Times - The Business Journals
Now Is The Time To Build A Position In Kronos Bio Inc (NASDAQ:KRON) - Marketing Sentinel
KRON’s Stock Market Labyrinth: Navigating 2023’s Gains and Declines - investchronicle.com
Kronos Bio Enters Deal to be Acquired by Concentra Biosciences; Shares Fall - marketscreener.com
Today’s watch list includes Kronos Bio Inc (NASDAQ:KRON) stock - uspostnews.com
Kronos Bio stock hits 52-week low at $0.68 amid market challenges - Investing.com India
After hunt for alternatives, Kronos Bio selects Tang Capital’s Concentra for a deal - Endpoints News
Kronos Bio (KRON) to be Acquired by Concentra Biosciences in Strategic Merger | KRON Stock News - GuruFocus
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders - The Joplin Globe
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders - The Joplin Globe
Concentra To Acquire Kronos Bio - Nasdaq
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right - The Manila Times
Kronos Bio agrees to Concentra Biosciences acquisition - Investing.com
Kronos Bio Enters into Agreement to Be Acquired by - GlobeNewswire
Kronos Bio (KRON) Projected to Announce Quarterly Earnings on Thursday - Defense World
Renaissance Technologies LLC Has $1.11 Million Position in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Kronos Bio ends lease early, pays $1.4 million settlement - Investing.com Australia
Kronos Bio ends lease early, pays $1.4 million settlement By Investing.com - Investing.com Canada
Kronos Bio Announces Lease Termination Agreement - TipRanks
Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors - The Manila Times
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
Kronos Bio Reports 2024 Financial Results - TipRanks
크로노스 (KRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.11%
1.70%
자본화:
|
볼륨(24시간):